Cardiac ultrasound findings in infants with severe (hurler phenotype) untreated mucopolysaccharidosis (MPS) type i

JIMD Reports

Volumn 10, Issue , 2013, Pages 87-94

  Schroeder, L ^a   Orchard, P ^a   Whitley, C B ^a   Berry, J M ^a   Tolar, J ^a   Miller, W ^a   Braunlin, E A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Aortic valve; Cardiac valve; Enzyme replacement therapy; Mitral regurgitation; Mitral valve

Indexed keywords

EID: 84885433803     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2012_208     Document Type: Chapter

References (26)

1. Braunlin EA (2012) Cardiac involvement in the MPS disorders. In: Moller JH, Hoffman JIE (eds) Pediatric cardiovascular medicine. Blackwell, Hoboken, pp 982–991
2. Braunlin EA, Stauffer NR, Peters CH et al (2003) Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 92:882–886
3. Braunlin EA, Berry JM, Whitley CB (2006) Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 98:416–418
4. Braunlin EA, Tolar J, Mackey-Bojack S, Masinde T, Krivit W, Schoen FJ (2011) Clear cells in the atrioventricular valves of infants with severe human mucopolysaccharidosis (Hurler syndrome) are activated valvular interstitial cells. Cardiovasc Pathol 20:315–321
5. Brosius FC, Roberts WC (1981) Coronary artery disease in the hurler syndrome: qualitative and quantitative analysis of the extent of coronary artery narrowing at necropsy in six children. Am J Cardiol 47:649–653
6. Dangel JH (1998) Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders – clinical and echocardiographic findings in 64 patients. Eur J Pediatr 57:534–538
7. Fesslova V, Corti P, Sersale G et al (2009) The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 19:170–178
8. Gabrielli O, Clarke LA, Bruni S, Coppa GV (2010) Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5 year follow-up. Pediatrics 125:e183–187
9. Gillingsrud EO, Krivit W, Summers CG (1998) Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology 105:1099–1105
10. Gross DM, Williams JC, Caprioli C, Dominquez B, Howell RR (1988) Echocardiographic abnormalities in the mucopolysaccharide storage diseases. Am J Cardiol 61:170–176
11. Hatle L, Angelsen B (1985) Doppler ultrasound in cardiology: physical principles and clinical applications, 2nd edn. Lea-Febiger, Philadelphia, p 93
12. http://graphpad.com
13. Gross DM, Williams JC, Caprioli C, Dominquez B, Howell RR (1988) Echocardiographic abnormalities in the mucopolysaccharide storage diseases. Am J Cardiol 61:170–176
14. Lai WW, Geva T, Shirali GS (2006) Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr 19:1413–1430
15. Leal GN, de Paula AC, Leone C, Kim CA (2010) Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 20:254–261
16. Lopez L, Colan SD, Frommelt PC et al (2010) Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr 23:465–495
17. McGill JJ, Inwood AC, Corman DJ et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age – a sibling control study. Clin Genet 77:492–498
18. Mohan UR, Hay AA, Cleary MA, Wraith JE, Patel RG (2002) Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr 91:799–804
19. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Valle D, Sly WS (eds) The metabolic basis of inherited diseases, 8th edn. McGraw-Hill, New York, pp 3421–3452
20. Schieken RM, Kerber RE, Ionasescu VV, Zellweger H (1975) Cardiac manifestations of the mucopolysaccharidoses. Circulation 52:700–705
21. Sifuentes M, Doroshow R, Hoft R et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90:171–180
22. Tylki-Szymanska A, Jurecka A, Zuber Z, Rozdzynska A, Marucha J, Czartorynska B (2012) Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr 101:e42–47
23. Van den Broek L, Backx PC, Coolen H et al (2011) Fatal coronary artery disease in an infant with severe mucopolysaccharidosis type I. Pediatrics 127:e1343–1346
24. Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S (2004) Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 24:97–101
25. Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jungst B-K (1995) Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 154:98–101
26. Wiseman DH, Mercer J, Tylee K et al (2012) Management of mucopolysaccharidosis type IH (Hurler’s Syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution’s experience. J Inherit Metab Dis. doi:10.1007/s10545-012-9500-3